|
1
|
Scott K, Hayden PJ, Will A, Wheatley K and
Coyne I: Bortezomib for the treatment of multiple myeloma. Cochrane
Database Syst Rev Apr. 4:CD0108162016.
|
|
2
|
Vélez R, Turesson I, Landgren O,
Kristinsson SY and Cuzick J: Incidence of multiple myeloma in Great
Britain, Sweden, and Malmö, Sweden: The impact of differences in
case ascertainment on observed incidence trends. BMJ Open.
6:e0095842016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lu J: The changes in the multiple myeloma
diagnostic criteria and its impact on treatment. Zhongguo Zhong Liu
Lin Chuang. 21:819–822. 2014.(In Chinese).
|
|
4
|
Dong W, Cai JH, Yang H and Zhai X:
Clinical efficacy of FVADT in the treatment of multiple myeloma.
Guangdong Yi Xue. 32:1746–1748. 2011.(In Chinese).
|
|
5
|
Lee JW, Kang HJ, Kim S, Lee SH, Yu KS, Kim
NH, Jang MK, Kim H, Song SH, Park JD, et al: Favorable outcome of
hematopoietic stem cell transplantation using a targeted once-daily
intravenous busulfan-fludarabine-etoposide regimen in pediatric and
infant acute lymphoblastic leukemia patients. Biol Blood Marrow
Transplant. 21:190–195. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bolomsky A, Schreder M, Meißner T, Hose D,
Ludwig H, Pfeifer S and Zojer N: Immunomodulatory drugs thalidomide
and lenalidomide affect osteoblast differentiation of human bone
marrow stromal cells in vitro. Exp Hematol. 42:516–525. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Willan J, Eyre TA, Sharpley F, Watson C,
King AJ and Ramasamy K: Multiple myeloma in the very elderly
patient: Challenges and solutions. Clin Interv Aging. 11:423–435.
2016.PubMed/NCBI
|
|
8
|
Maiso P, Huynh D, Moschetta M, Sacco A,
Aljawai Y, Mishima Y, Asara JM, Roccaro AM, Kimmelman AC and
Ghobrial IM: Metabolic signature identifies novel targets for drug
resistance in multiple myeloma. Cancer Res. 75:2071–2082. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Amirshahrokhi K and Khalili AR: The effect
of thalidomide on ethanol-induced gastric mucosal damage in mice:
Involvement of inflammatory cytokines and nitric oxide. Chem Biol
Interact. 225:63–69. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang CL, He ZM, Zhou LT, Shi YY, Chen Y,
Zhang L, Song L, Ding B and Liu DS: Effect of low-dose Lenalidomide
in combination with Dexamethasone on refractory or relapsed
multiple myeloma in the elderly. Zhong Nua Lao Nian Yi Xue Za Zhi.
33:1191–1193. 2014.(In Chinese).
|
|
11
|
Li X, Sun W, Jin F, Chen S, Zhong Y, Hu Y,
Zhang J, An N, Shen M and Huang Z: Clinical observation of DECP
combination chemotherapy for relapsing and refractory multiple
myeloma patients with extramedullary plasmacytomas. Zhonghua Yi Xue
Za Zhi. 94:1258–1260. 2014.(In Chinese). PubMed/NCBI
|
|
12
|
Chen X, Duan N, Zhang C and Zhang W:
Survivin and tumorigenesis: Molecular mechanisms and therapeutic
strategies. J Cancer. 7:314–323. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun L, Zhao Y, Shi H, Ma C and Wei L:
LMP-1 induces survivin expression to inhibit cell apoptosis through
the NF-κB and PI3K/Akt signaling pathways in nasal NK/T-cell
lymphoma. Oncol Rep. 33:2253–2260. 2015.PubMed/NCBI
|
|
14
|
Sokołowska J, Urbańska K, Giziński S,
Wysocka A, Cywińska A and Lechowski R: Survivin expression in
canine lymphomas in relation with proliferative markers. Pol J Vet
Sci. 18:113–122. 2015.PubMed/NCBI
|
|
15
|
Bobustuc GC, Patel A, Thompson M,
Srivenugopal KS, Frick J, Weese J and Konduri SD: MGMT inhibition
suppresses survivin expression in pancreatic cancer. Pancreas.
44:626–635. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kasamatsu J, Takahashi S, Azuma M,
Matsumoto M, Morii-Sakai A, Imamura M, Teshima T, Takahashi A,
Hirohashi Y, Torigoe T, et al: PolyI:C and mouse survivin
artificially embedding human 2B peptide induce a CD4+ T cell
response to autologous survivin in HLA-A*2402 transgenic mice.
Immunobiology. 220:74–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hernandez JM, Farma JM, Coppola D, Hakam
A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ and Shibata D:
Expression of the antiapoptotic protein survivin in colon cancer.
Clin Colorectal Cancer. 10:188–193. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu CJ, Ou JH, Wang ML, Jialielihan N and
Liu YH: Elevated survivin mediated multidrug resistance and reduced
apoptosis in breast cancer stem cells. J BUON. 20:1287–1294.
2015.PubMed/NCBI
|
|
19
|
Rajkumar SV: Evolving diagnostic criteria
for multiple myeloma. Hematology Am Soc Hematol Educ Program.
2015:272–278. 2015.PubMed/NCBI
|
|
20
|
Su YT, Xie XS, Sun H, Ma J, Wan DM and Liu
YF: Clinical Features of 46 Multiple Myeloma Patients with
Different Renal Pathology. Zhongguo Shi Yan Xue Ye Xue Za Zhi.
24:487–491. 2016.(In Chinese). PubMed/NCBI
|
|
21
|
Deng SH, Xu Y, Mai YJ, Wang YF, Zhao YZ,
Zou DH and Qiu LG: Analysis of the international staging system of
multiple myeloma and its comparison with the DS and IFM staging
system in 122 Chinese patients. Zhonghua Xue Ye Xue Za Zhi.
29:217–21. 2008.(In Chinese). PubMed/NCBI
|
|
22
|
Ooi MG, de Mel S and Chng WJ: Risk
stratification in multiple myeloma. Curr Hematol Malig Rep.
11:137–147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ndebele P: The Declaration of Helsinki, 50
years later. JAMA. 310:2145–2146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dueck AC, Mendoza TR, Mitchell SA, Reeve
BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM,
O'Mara AM, et al: National Cancer Institute PRO-CTCAE Study Group:
Validity and reliability of the US National Cancer Institute's
patient-reported outcomes version of the common terminology
criteria for adverse events (PRO-CTCAE). JAMA Oncol. 1:1051–1059.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
El Deeb NM and Abdelzaher E: Stem cell
markers OCT4 and nestin in laryngeal squamous cell carcinoma and
their relation to survivin expression. Pathol Res Pract.
210:751–758. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lanza F, Campioni DC, Hellmann A, Milone
G, Wahlin A, Walewski J, Spedini P, Fiamenghi C, Cuneo A, Knopińska
W, et al: Individual quality assessment of autografting by
probability estimation for clinical endpoints: A prospective
validation study from the European group for blood and marrow
transplantation. Biol Blood Marrow Transplant. 19:1670–1676. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rajkumar SV and Kumar S: Multiple myeloma:
Diagnosis and treatment. Mayo Clin Proc. 91:101–119. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Xu P, Chen Y, Fan Q, Li J, Zhao W,
Mi J and Yan H: Novel agent induction therapy alone or followed by
autologous stem cell transplantation in younger patients with
multiple myeloma: A single-center retrospective study of 114 cases.
Mol Clin Oncol. 4:107–113. 2016.PubMed/NCBI
|
|
29
|
Yang CM, Meng HT, Liu H and Qian WB:
Effects of fludarabine on apoptosis and gene expression profile in
multiple myeloma cells. Zhonghua Xue Ye Xue Za Zhi. 31:659–662.
2010.(In Chinese). PubMed/NCBI
|
|
30
|
Gozzetti A, Candi V, Fabbri A, Schiattone
L, Cencini E, Lauria F, Frasconi A, Crupi R, Raspadori D, Papini G,
et al: Chemoimmunotherapy with oral low-dose fludarabine,
cyclophosphamide and rituximab (old-FCR) as treatment for elderly
patients with chronic lymphocytic leukaemia. Leuk Res. 38:891–895.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao Y, Ma G, Liu S, Teng Y, Wang Y and Su
Y: Thalidomide and multiple myeloma serum synergistically induce a
hemostatic imbalance in endothelial cells in vitro. Thromb Res.
135:1154–1159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Anderson KC: Moving disease biology from
the lab to the clinic. Cancer. 97(Suppl): 796–801. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Slawinska-Brych A, Zdzisinska B,
Mizerska-Dudka M and Kandefer-Szerszen M: Induction of apoptosis in
multiple myeloma cells by a statin-thalidomide combination can be
enhanced by p38 MAPK inhibition. Leuk Res. 37:586–594. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
El-Aarag BY, Kasai T, Zahran MA, Zakhary
NI, Shigehiro T, Sekhar SC, Agwa HS, Mizutani A, Murakami H, Kakuta
H and Seno M: In vitro anti-proliferative and anti-angiogenic
activities of thalidomide dithiocarbamate analogs. Int
Immunopharmacol. 21:283–292. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Athanasoula KCh, Gogas H, Polonifi K,
Vaiopoulos AG, Polyzos A and Mantzourani M: Survivin beyond
physiology: Orchestration of multistep carcinogenesis and
therapeutic potentials. Cancer Lett. 347:175–182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang L, Kang Y, Zheng W, Li L, Shi L and
Ma X: Effect on apoptosis and cell cycle of recombinant double
negative dominant mutation Survivin (T34/117A) in breast cancer
cell B-Cap-37. Biomed Pharmacother. 68:277–284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Majithia N, Vincent Rajkumar S, Lacy MQ,
Buadi FK, Dispenzieri A, Gertz MA, Hayman SR, Dingli D, Kapoor P,
Hwa L, et al: Outcomes of primary refractory multiple myeloma and
the impact of novel therapies. Am J Hematol. 90:981–985. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fukuda S, Foster RG, Porter SB and Pelus
LM: The antiapoptosis protein survivin is associated with cell
cycle entry of normal cord blood CD34(+) cells and modulates cell
cycle and proliferation of mouse hematopoietic progenitor cells.
Blood. 100:2463–2471. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Poomsawat S, Punyasingh J and Vejchapipat
P: Overexpression of survivin and caspase 3 in oral carcinogenesis.
Appl Immunohistochem Mol Morphol. 22:65–71. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tsubaki M, Takeda T, Ogawa N, Sakamoto K,
Shimaoka H, Fujita A, Itoh T, Imano M, Ishizaka T, Satou T and
Nishida S: Overexpression of survivin via activation of ERK1/2, Akt
and NF-κB plays a central role in vincristine resistance in
multiple myeloma cells. Leuk Res. 39:445–452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Oto OA, Paydas S, Tanriverdi K, Seydaoglu
G, Yavuz S and Disel U: Survivin and EPR-1 expression in acute
leukemias: Prognostic significance and review of the literature.
Leuk Res. 31:1495–1501. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Huang J, Lyu H, Wang J and Liu B:
Influence of survivin-targeted therapy on chemosensitivity in the
treatment of acute myeloid leukemia. Cancer Lett. 366:160–172.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Adida C, Recher C, Raffoux E, Daniel MT,
Taksin AL, Rousselot P, Sigaux F, Degos L, Altieri DC and Dombret
H: Expression and prognostic significance of survivin in de novo
acute myeloid leukaemia. Br J Haematol. 111:196–203. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tsubaki M, Komai M, Itoh T, Imano M,
Sakamoto K, Shimaoka H, Takeda T, Ogawa N, Mashimo K, Fujiwara D,
et al: By inhibiting Src, verapamil and dasatinib overcome
multidrug resistance via increased expression of Bim and decreased
expressions of MDR1 and survivin in human multidrug-resistant
myeloma cell. Leuk Res. 38:121–130. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen S, Wang Y, An L, Fei ZT and Li T: The
diagnostic value of survivin in malignant pleural effusion: A
meta-analysis. Clin Chim Acta. 441:142–147. 2015. View Article : Google Scholar : PubMed/NCBI
|
